| Date Filed | Type | Description |
| 05/25/2023 |
SC 13G
| Avidity Partners Management LP reports a 6.2% stake in NanoString Technologies, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.2% stake in ESSA Pharma Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 8.1% stake in Altimmune Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.7% stake in Syndax Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.9% stake in Kezar Life Sciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 7.9% stake in IDEAYA Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4% stake in Alpine Immune Sciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.9% stake in Karyopharm Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 3.3% stake in Gritstone bio, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 8.2% stake in Akero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 5.1% stake in Cyteir Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.1% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 4.6% stake in Phathom Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9.3% stake in Arvinas, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 0.6% stake in IVERIC bio, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 0% stake in Oncosec Medical Incorporated |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 0% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 9% stake in Zentalis Pharmaceuticals, Inc. |
| 02/02/2023 |
SC 13G
| Avidity Partners Management LP reports a 8.7% stake in Praxis Precision Medicines, Inc. |
| 12/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/20/2022 |
SC 13G
| Avidity Partners Management LP reports a 9.9% stake in Syros Pharmaceuticals, Inc. |
| 09/16/2022 |
SC 13G
| Avidity Partners Management LP reports a 6.9% stake in Akero Therapeutics, Inc. |
| 06/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 6.6% stake in IDEAYA Biosciences, Inc. |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 9.9% stake in Syndax Pharmaceuticals, Inc. |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 9.3% stake in Scynexis, Inc. |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 7.5% stake in Oncosec Medical Incorporated |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 5.9% stake in Viridian Therapeutics, Inc. |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 9.2% stake in PhaseBio Pharmaceuticals, Inc. |
| 02/11/2022 |
SC 13G/A
| Avidity Partners Management LP reports a 6.1% stake in IVERIC bio, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|